Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
Carlyle price target lowered to $47 from $50 at BofA
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...
The Carlyle Group (NASDAQ:CG) Cut to Sell at StockNews.com
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
BioPharma Dive1d
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Carlyle Acquires Highway-Roop Auto Parts Platform in India
Carlyle Group Inc. completed its acquisition of a controlling stake in an Indian auto-parts making platform formed by the ...
The Aspen Times19h
Mountain Mayhem: Bemelmans Bar x Mytheresa take Aspen
For the very first time, the storied Bemelmans Bar within The Carlyle, A Rosewood Hotel, has popped up outside of its Upper ...
The Search For 7% Investment Grade Yields, Part 2: Carlyle And Its Baby Bond
The Carlyle Group offers solid investment-grade debt with consistent dividends. Learn why CG stock’s baby bond, CGABL, is a ...